Table 3.
Five-year survival by HER2/HR status among women aged 20–49 years diagnosed with stage I-III breast cancer, 2010–2015, SEER 18 registries
| 20–29 Years | 30–39 Years | 40–49 Years | ||||
|---|---|---|---|---|---|---|
| N | Survival (95% CI) | N | Survival (95% CI) | N | Survival (95% CI) | |
| Analytic sample | ||||||
| HER2+/HR+ | 326 | 91.9 (86.1, 95.3) | 2,238 | 94.6 (93.2, 95.8) | 5,872 | 94.8 (94.0, 95.5) |
| HER2+/HR− | 107 | 91.8 (78.3, 97.0) | 867 | 88.6 (85.4, 91.2) | 2,251 | 89.2 (87.4, 90.8) |
| HER2−/HR+ | 735 | 89.0 (85.5, 91.7) | 6,793 | 90.9 (89.9, 91.8) | 30,912 | 95.3 (95.0, 95.6) |
| HER2−/HR− | 361 | 79.3 (73.3, 84.0) | 2,399 | 78.3 (76.2, 80.3) | 5,757 | 80.1 (78.8, 81.3) |
| Stage I | ||||||
| HER2+/HR+ | 89 | 98.5 (89.9, 99.8) | 586 | 99.4 (98.1, 99.8) | 2,169 | 98.2 (97.3, 98.8) |
| HER2+/HR− | 32 | 100 | 200 | 95.1 (89.4, 97.8) | 734 | 95.6 (92.8, 97.3) |
| HER2−/HR+ | 219 | 97.0 (92.1, 98.9) | 2,259 | 96.9 (95.6, 97.8) | 15,247 | 98.5 (98.2, 98.8) |
| HER2−/HR− | 62 | 90.2 (75.2, 96.3) | 494 | 92.8 (89.5, 95.1) | 1,682 | 93.0 (91.2, 94.4) |
| Stage II | ||||||
| HER2+/HR+ | 168 | 95.6 (85.8, 98.7) | >1,171 | 95.7 (93.7, 97.1) | 2,660 | 95.2 (93.9, 96.2) |
| HER2+/HR− | 46 | 95.5 (71.9, 99.3) | 406 | 92.5 (88.0, 95.3) | 969 | 92.4 (89.9, 94.3) |
| HER2−/HR+ | 354 | 90.4 (85.0, 93.9) | 3,185 | 92.1 (90.7, 93.3) | 11,549 | 95.0 (94.4, 95.5) |
| HER2−/HR− | 209 | 83.0 (74.4, 88.9) | 1,430 | 83.4 (80.7, 85.7) | 3,005 | 82.4 (80.6, 84.0) |
| Stage III | ||||||
| HER2+/HR+ | 69 | 74.9 (57.0, 86.2) | 481 | 86.5 (81.8, 90.0) | 1,043 | 87.1 (84.2, 89.5) |
| HER2+/HR− | 29 | 77.7 (42.7, 92.8) | 261 | 78.4 (70.7, 84.3) | 548 | 75.7 (70.7, 80.0) |
| HER2−/HR+ | 162 | 73.8 (63.1, 81.8) | 1,349 | 78.4 (75.3, 81.2) | 4,116 | 84.4 (82.9, 85.8) |
| HER2−/HR− | 90 | 62.6 (50.0, 72.9) | 475 | 48.4 (42.9, 53.7) | 1,070 | 54.2 (50.5, 57.6) |
| Non-Hispanic white | ||||||
| HER2+/HR+ | 175 | 92.9 (84.2, 96.9) | 1,218 | 95.3 (93.4, 96.7) | 3,322 | 95.4 (94.3, 96.3) |
| HER2+/HR− | 54 | 89.8 (64.8, 97.4) | 438 | 91.0 (86.7, 93.9) | 1,125 | 90.3 (87.7, 92.4) |
| HER2−/HR+ | 366 | 88.9 (83.7, 92.4) | 3,574 | 91.4 (90.1, 92.6) | 18,883 | 95.9 (95.6, 96.3) |
| HER2−/HR− | 162 | 84.0 (75.9, 89.5) | 1,139 | 80.4 (77.4, 83.1) | 2,970 | 82.2 (80.5, 83.8) |
| Non-Hispanic black | ||||||
| HER2+/HR+ | 47 | 87.7 (64.8, 96.1) | 310 | 90.1 (84.8, 93.6) | 700 | 89.7 (86.2, 92.4) |
| HER2+/HR− | 18 | 90.9 (50.8, 98.7) | 113 | 86.4 (76.3, 92.4) | 356 | 80.4 (74.3, 85.1) |
| HER2−/HR+ | 124 | 89.4 (79.2, 94.8) | 866 | 84.5 (81.0, 87.4) | 3,083 | 89.7 (88.2, 91.0) |
| HER2−/HR− | 79 | 72.6 (56.6, 83.5) | 464 | 72.3 (67.2, 76.7) | 1,226 | 74.1 (71.0, 76.9) |
| Non-Hispanic Asian or Pacific Islander | ||||||
| HER2+/HR+ | 38 | 100 | 272 | 97.3 (93.3, 98.9) | 744 | 97.4 (95.4, 98.6) |
| HER2+/HR− | 12 | 100 | 117 | 88.7 (75.9, 94.9) | 325 | 92.9 (88.5, 95.6) |
| HER2−/HR+ | 75 | 97.9 (85.8, 99.7) | 938 | 94.0 (91.3, 95.9) | 3,809 | 97.2 (96.3, 97.8) |
| HER2−/HR− | 30 | 76.8 (49.4, 90.6) | 214 | 81.2 (73.7, 86.7) | 470 | 84.2 (79.5, 88.0) |
| Hispanic (all races) | ||||||
| HER2+/HR+ | 59 | 87.9 (72.0, 95.1) | 405 | 94.3 (89.7, 96.9) | 1,036 | 94.4 (92.0, 96.1) |
| HER2+/HR− | 21 | 94.1 (65.0, 99.2) | 183 | 84.6 (75.3, 90.7) | 420 | 91.2 (87.1, 94.0) |
| HER2−/HR+ | 163 | 84.6 (74.9, 90.8) | 1,336 | 91.4 (89.1, 93.2) | 4,807 | 95.0 (94.1, 95.8) |
| HER2−/HR− | 85 | 79.1 (66.8, 87.2) | 547 | 77.8 (72.8, 81.9) | 1,033 | 78.7 (75.2, 81.8) |
Abbreviations: CI, confidence interval; HER2, human epidermal growth factor receptor-2; HR, hormone receptor; SEER, Surveillance, Epidemiology, and End Results.
Results for non-Hispanic American Indian/Alaska Native women aged 20–49 years (n=366) and non-Hispanic women of unknown race aged 20–49 years (n=301) were not presented due to sparse totals for these strata.